Diagnostic accuracy of 11C-methionine PET in detecting neuropathologically confirmed recurrent brain tumor after radiation therapy

被引:8
作者
Kits, Annika [1 ]
Martin, Heather [1 ]
Sanchez-Crespo, Alejandro [2 ]
Delgado, Anna F. [1 ,3 ]
机构
[1] Karolinska Univ Hosp, Dept Neuroradiol, R3 00, S-17176 Stockholm, Sweden
[2] Karolinska Univ Hosp, Med Radiat Phys & Nucl Med, Stockholm, Sweden
[3] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
关键词
Radiation injury; C-11-methionine PET; Radiosurgery; Brain tumor recurrence; Gamma-knife surgery; POSITRON-EMISSION-TOMOGRAPHY; DIFFERENTIAL-DIAGNOSIS; STEREOTACTIC RADIOSURGERY; GLIOMA RECURRENCE; C-11; METHIONINE; NECROSIS; DISCREPANCIES; MRI;
D O I
10.1007/s12149-017-1227-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This study aims to determine the diagnostic test accuracy (DTA) of C-11-methionine (MET) PET in the discrimination between recurrent tumor and radiation-induced injury in neuropathologically confirmed cases. A retrospective cohort of 30 patients with previously irradiated intracranial tumors (23 gliomas, 6 metastases, and 1 meningioma) was included. All patients underwent a preoperative MET PET and postoperative neuropathological analysis. Maximum and mean standardized uptake values (SUV) were obtained in the lesion, in the contralateral mirror region, and in the contralateral frontal cortex. Lesion-to-background SUV ratios (SUR mirror and SUR cortex) were then calculated. The Mann-Whitney U test was used to evaluate differences in SUV ratios between confirmed recurrent tumor and radiation injury. DTA was determined through receiver operating characteristic (ROC) analysis. Twenty-one patients had recurrent tumor and nine had radiation injury. The area under the ROC curve (AUC) was 0.89 for SUR(max)mirror and 0.88 for SUR(max)cortex. The mean (SD) of SUR(max)mirror was 2.37 (0.58) in tumor recurrence and 1.57 (0.40) in radiation necrosis (P ae 0.001). The corresponding values for SUR(max)cortex were 2.13 (0.50) and 1.45 (0.37) (P = 0.001). Clinically relevant cutoffs were SUR(max)mirror ae 1.99 giving a specificity of 100% for tumor recurrence with a sensitivity of 76% and SUR(max)cortex ae 1.58 giving a sensitivity and specificity of 90 and 78%, respectively. Based on neuropathologically confirmed cases, the DTA of SUR(max)mirror and SUR(max)cortex from C-11-methionine PET was high when discriminating recurrent tumor from radiation injury.
引用
收藏
页码:132 / 141
页数:10
相关论文
共 50 条
  • [1] Diagnostic accuracy of 11C-methionine PET in detecting neuropathologically confirmed recurrent brain tumor after radiation therapy
    Annika Kits
    Heather Martin
    Alejandro Sanchez-Crespo
    Anna F. Delgado
    Annals of Nuclear Medicine, 2018, 32 : 132 - 141
  • [2] Prospective study of 11C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment
    Yomo, Shoji
    Oguchi, Kazuhiro
    BMC CANCER, 2017, 17 : 1
  • [3] Value of 11C-methionine PET in imaging brain tumours and metastases
    Glaudemans, Andor W. J. M.
    Enting, Roelien H.
    Heesters, Mart A. A. M.
    Dierckx, Rudi A. J. O.
    van Rheenen, Ronald W. J.
    Walenkamp, Annemiek M. E.
    Slart, Riemer H. J. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) : 615 - 635
  • [4] Determination of brain tumor recurrence using 11C-methionine positron emission tomography after radiotherapy
    Yamaguchi, Shigeru
    Hirata, Kenji
    Okamoto, Michinari
    Shimosegawa, Eku
    Hatazawa, Jun
    Hirayama, Ryuichi
    Kagawa, Naoki
    Kishima, Haruhiko
    Oriuchi, Noboru
    Fujii, Masazumi
    Kobayashi, Kentaro
    Kobayashi, Hiroyuki
    Terasaka, Shunsuke
    Nishijima, Ken-ichi
    Kuge, Yuji
    Ito, Yoichi M.
    Nishihara, Hiroshi
    Tamaki, Nagara
    Shiga, Tohru
    CANCER SCIENCE, 2021, 112 (10) : 4246 - 4256
  • [5] Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm
    Yamane, Tomohiko
    Sakamoto, Setsu
    Senda, Michio
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (04) : 685 - 690
  • [6] 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas
    B. N. T. Tang
    M. Levivier
    M. Heureux
    D. Wikler
    N. Massager
    D. Devriendt
    P. David
    N. Dumarey
    B. Corvilain
    S. Goldman
    European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33 : 169 - 178
  • [7] 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas
    Tang, BNT
    Levivier, M
    Heureux, M
    Wikler, D
    Massager, N
    Devriendt, D
    David, P
    Dumarey, N
    Corvilain, B
    Goldman, S
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (02) : 169 - 178
  • [8] 11C-methionine PET/CT findings in benign brain disease
    Nakajima, Reiko
    Kimura, Ken
    Abe, Koichiro
    Sakai, Shuji
    JAPANESE JOURNAL OF RADIOLOGY, 2017, 35 (06) : 279 - 288
  • [9] Diagnostic and Prognostic Value of 11C-Methionine PET for Nonenhancing Gliomas
    Takano, K.
    Kinoshita, M.
    Arita, H.
    Okita, Y.
    Chiba, Y.
    Kagawa, N.
    Fujimoto, Y.
    Kishima, H.
    Kanemura, Y.
    Nonaka, M.
    Nakajima, S.
    Shimosegawa, E.
    Hatazawa, J.
    Hashimoto, N.
    Yoshimine, T.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2016, 37 (01) : 44 - 50
  • [10] Prognostic value of post-treatment metabolic tumor volume from 11C-methionine PET/CT in recurrent malignant glioma
    Jung, Tae-Young
    Min, Jung-Joon
    Bom, Hee-Seung
    Jung, Shin
    Kim, In-Young
    Lim, Sa-Hoe
    Kim, Dong-Yeon
    Kwon, Seong Young
    NEUROSURGICAL REVIEW, 2017, 40 (02) : 223 - 229